<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ramani H</submitter><funding>NIA NIH HHS</funding><funding>NIH HHS</funding><pagination>481</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11987946</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(7)</volume><pubmed_abstract>People with HIV (PWH) have an increased risk of developing cardiovascular disease (CVD). Our recent data demonstrated that the multi-isoform proinflammatory cytokine IL-32 is upregulated in PWH and is associated with arterial stiffness and subclinical atherosclerosis. However, the mechanisms by which IL-32 contributes to the pathogenesis of these diseases remain unclear. Here, we show that while the less expressed IL-32α isoform induces the differentiation of human classical monocytes into the calcium-resorbing osteoclast cells, the dominantly expressed isoforms IL-32β and IL-32γ suppress this function through the inhibition of TGF-β and induce the differentiation of monocytes into the calcium-depositing osteocalcin+ osteoblasts. These results aligned with the increase in plasma levels of </pubmed_abstract><journal>Cells</journal><pubmed_title>Opposite Roles of IL-32α Versus IL-32β/γ Isoforms in Promoting Monocyte-Derived Osteoblast/Osteoclast Differentiation and Vascular Calcification in People with HIV.</pubmed_title><pmcid>PMC11987946</pmcid><funding_grant_id>2R01AG054324-08A1</funding_grant_id><funding_grant_id>R01 AG054324</funding_grant_id><pubmed_authors>Kizer JR</pubmed_authors><pubmed_authors>Sylla M</pubmed_authors><pubmed_authors>Thomas R</pubmed_authors><pubmed_authors>Jenabian MA</pubmed_authors><pubmed_authors>Durand M</pubmed_authors><pubmed_authors>Martel-Laferriere V</pubmed_authors><pubmed_authors>Tremblay CL</pubmed_authors><pubmed_authors>Ramani H</pubmed_authors><pubmed_authors>Cloutier G</pubmed_authors><pubmed_authors>Chomont N</pubmed_authors><pubmed_authors>Chartrand-Lefebvre C</pubmed_authors><pubmed_authors>Bertrand F</pubmed_authors><pubmed_authors>Landay AL</pubmed_authors><pubmed_authors>Peet MM</pubmed_authors><pubmed_authors>Ancuta P</pubmed_authors><pubmed_authors>Fortin C</pubmed_authors><pubmed_authors>Cleret-Buhot A</pubmed_authors><pubmed_authors>Trottier B</pubmed_authors><pubmed_authors>Hanna DB</pubmed_authors><pubmed_authors>Allard L</pubmed_authors><pubmed_authors>El-Far M</pubmed_authors><pubmed_authors>Sadouni M</pubmed_authors><pubmed_authors>Bunet R</pubmed_authors><pubmed_authors>Routy JP</pubmed_authors><pubmed_authors>Kaplan RC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Opposite Roles of IL-32α Versus IL-32β/γ Isoforms in Promoting Monocyte-Derived Osteoblast/Osteoclast Differentiation and Vascular Calcification in People with HIV.</name><description>People with HIV (PWH) have an increased risk of developing cardiovascular disease (CVD). Our recent data demonstrated that the multi-isoform proinflammatory cytokine IL-32 is upregulated in PWH and is associated with arterial stiffness and subclinical atherosclerosis. However, the mechanisms by which IL-32 contributes to the pathogenesis of these diseases remain unclear. Here, we show that while the less expressed IL-32α isoform induces the differentiation of human classical monocytes into the calcium-resorbing osteoclast cells, the dominantly expressed isoforms IL-32β and IL-32γ suppress this function through the inhibition of TGF-β and induce the differentiation of monocytes into the calcium-depositing osteocalcin+ osteoblasts. These results aligned with the increase in plasma levels of </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2025-07-06T03:05:40.974Z</modification><creation>2025-07-06T03:05:40.974Z</creation></dates><accession>S-EPMC11987946</accession><cross_references><pubmed>40214435</pubmed><doi>10.3390/cells14070481</doi></cross_references></HashMap>